WithdrawnPhase 2NCT04795869

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Studying Angioimmunoblastic T-cell lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Northwestern University
Principal Investigator
Jonathan Moreira, MD
Northwestern University
Intervention
Brentuximab Vedotin(drug)
Eligibility
18 years · All sexes
Timeline
2020 – 2029

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Seagen Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04795869 on ClinicalTrials.gov

Other trials for Angioimmunoblastic T-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Angioimmunoblastic T-cell lymphoma →

← Back to all trials